News & Videos - CURETIS

Amsterdam, The Netherlands, and Holzgerlingen, Germany, July 01, 2020, 08:30 am CEST - Curetis N.V. in liquidatie (the "Company") today announced the publication of its audited 2019 full year financial results and 2019 Annual Report. Originally scheduled for April 30, 2020, this was delayed due to the impact of the COVID-19 pandemic on the Company’s finance department’s operations, its external advisors, including a purely remote and off-site auditing effort required as part of the...

Amsterdam, The Netherlands, and Holzgerlingen, Germany, April 30, 2020, 08:00 am CET - Curetis N.V. in liquidatie (the " Company ") today announced that the publication of its audited 2019 full year financial results and 2019 Annual Report originally scheduled for April 30, 2020 will be delayed to a later date expected in May 2020. The delay is caused by the impact of the COVID-19 pandemic on the Company’s finance department’s operations, its external advisors, including a purely remote and...

Amsterdam, the Netherlands, Holzgerlingen, Germany April 20, 2020, 8:00 am CEST - Curetis N.V. in liquidatie (the " Company ") announces that the liquidators of the Company have resolved upon a liquidation distribution in advance to the respective shareholders of the Company (the “ Shareholders ”), in an amount equal to the value of 1,622,568 shares of OpGen Inc., a Delaware corporation, common stock (the “ OpGen Shares ”), which distribution shall be satisfied in kind by transferring...

- Following approval of shareholders, companies sign German transfer agreement - Curetis GmbH and its subsidiaries Curetis USA Inc. and Ares Genetics GmbH are now wholly owned by OpGen, Inc. - OpGen consideration shares to be distributed to Curetis N.V. shareholders and Curetis N.V. to be dissolved and delisted from Euronext - Three Curetis N.V. Supervisory Board members resign to join newly formed OpGen Inc. board of directors Amsterdam, The Netherlands, and Holzgerlingen, Germany, April 01,...

Quorum achieved for OpGen stockholder vote on Curetis business combination with 99% of votes supporting transaction Transaction close anticipated by early April 2020 Combined OpGen and Curetis business generated $6 million in unaudited pro forma combined 2019 revenue (up from $4.5 million in 2018) First shipments of BGI SARS-CoV-2 rapid PCR kits completed by Curetis in Europe. Additional actions planned to address the global COVID-19 pandemic Amsterdam, the Netherlands, Holzgerlingen, Germany,...

- Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours - Test kit to be made available via Curetis’ European sales channels - Synergies with Curetis Unyvero HPN panel for pneumonia testing for bacterial co-infections in Covid-19 patients Holzgerlingen, Germany, March 16, 2020, 08:00 am CET - Curetis N.V. (the " Company " and together with its subsidiaries " Curetis "), a developer of next-level molecular diagnostic solutions, today announced that it starts offering a...

Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, March 10, 2020, 16:15 pm CET - Curetis N.V. (the " Company " and together with its subsidiaries " Curetis "), a developer of next-level molecular diagnostic solutions, reports that a Special Meeting of shareholders of OpGen, Inc. (“ OpGen ”) held today, March 10, 2020, in Washington DC, USA, to approve the business combination of Curetis and OpGen, was adjourned. Because a quorum was not represented at OpGen’s...

- Shareholders adopt all proposed resolutions - EGM votes clear way for closing of business combination with OpGen, Inc., subject to OpGen’s stockholders’ approval - Subsequently Curetis N.V. will be dissolved and shares of OpGen common stock are to be distributed to the shareholders of Curetis N.V. Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, March 10, 2020, XX:00 pm CET - Curetis N.V. (the " Company " and together with its subsidiaries " Curetis "), a...

Revenue increases by 64% to EUR 2.3 million, up from 1.4 million in 2018 More than tripled total contract order volume received year-over-year to about EUR 3.4 million 2019 Curetis N.V. shareholders to vote on March 10, 2020 on planned business combination with OpGen, Inc. Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, February 20, 2020, 08:00 am CET -- Curetis N.V. (the " Company " and, together with its subsidiaries, " Curetis "), a developer of next-level...

Exclusive distribution agreement for initial term of 3 years Quaphaco commits to minimum purchase totaling about EUR 1.9 million during initial term Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, February 6, 2020, 08:00 am CET - Curetis N.V. (the " Company " and, together with its subsidiaries, " Curetis "), a developer of next-level molecular diagnostic solutions, today announced that it has entered into a distribution agreement with Quaphaco for Vietnam. Quaphaco,...

BGI Group responds to coronavirus crisis by providing reagent kits for molecular 2019-nCoV testing by next-generation sequencing and RT-PCR Ares Genetics to launch next-generation sequencing testing service for infection control and monitoring of 2019-nCoV evolution using BGI Group reagents Ares Genetics, Curetis Group and BGI Group to collaborate in the distribution of next-generations sequencing and PCR testing kits for 2019-nCoV Vienna, Austria, Holzgerlingen, Germany, and Shenzhen, China,...

Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, January 27, 2020, 08:00 am CET / 02:00 am EDT - Curetis N.V. (the " Company " and together with its subsidiaries " Curetis "), a developer of next-level molecular diagnostic solutions, today published the invitation to its Extraordinary General Meeting (EGM). The invitation follows the notice of effectiveness of the OpGen, Inc. S-4 filing received from the SEC on January 23, 2020. Curetis N.V. will hold the EGM on...

Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 23, 2020, 10:00 am CET - Curetis N.V. (the " Company " and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Curetis Group Companies will be attending several key conferences in the first half of 2020. February 2020 First Coast Infectious Disease/Clinical Microbiology Symposium 27th Annual Meeting January 31 – February 1, 2020 – Ponte Vedra Beach, FL...

Panel also includes atypical pathogens such as Pneumocystis jirovecii LRT BAL Panel expected to substantially increase total addressable market for Unyvero System in the U.S. Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, January 14, 2020, 08:00 am CET -- Curetis N.V. (the " Company " and, together with its subsidiaries, " Curetis "), a developer of next-level molecular diagnostic solutions, today announced the U.S. launch of its Unyvero LRT BAL Lower Respiratory...

Broad Unyvero LRT BAL panel also includes atypical pathogens such as Pneumocystis jirovecii Clearance expected to substantially increase total addressable market for Unyvero System in the U.S. Commercial launch in the U.S. expected for Q1-2020 Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, December 20, 2019, 23:30 CET -- Curetis N.V. (the " Company " and, together with its subsidiaries, " Curetis "), a developer of next-level molecular diagnostic solutions, today...

Ares Genetics selected for NVIDIA and AWS programs to accelerate commercialization of its AI-powered Universal Pathogenome Assay – ARESupa NVIDIA Inception program accelerates start-ups that revolutionize industries with advancements in AI Vienna, Austria, and Holzgerlingen, Germany, December 10, 2019, 08:00 am CET - Curetis N.V. (the " Company " and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned...

Prize awarded by the Vienna Economic Chamber to the most innovative companies in Vienna Ares Genetics´ awarded in the category Life Sciences for its AI-powered Universal Pathogenome Assay - ARESupa Vienna, Austria, and Holzgerlingen, Germany, November 25, 2019, 10:00 am CET - Curetis N.V. (the " Company " and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics was awarded the 2019...

All formal FDA requests for additional information answered Interactive review ongoing as review nears completion Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, November 25, 2019, 08:00 am CET -- Curetis N.V. (the " Company " and, together with its subsidiaries, " Curetis "), a developer of next-level molecular diagnostic solutions, today announced that the Company has filed its formal response to the FDA’s AI (Additional Information request letter regarding the...

- Signed IVD partnership for Ares Genetics - Progressed implementation of the Curetis - OpGen business combination with S4 filing - More than tripled total contract order volume received year-over-year to EUR 3.4 million in 9M-2019 - Revenue growth of approximately 16% - Near-term FDA decision on clearance of Unyvero LRT for BAL specimen expected Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, November 25, 2019, 07:00 am CET -- Curetis N.V. (the " Company " and,...

- Signed IVD partnership for Ares Genetics - Progressed implementation of the Curetis - OpGen business combination with S4 filing - More than tripled total contract order volume received year-over-year to EUR 3.4 million in 9M-2019 - Revenue growth of approximately 16% - Near-term FDA decision on clearance of Unyvero LRT for BAL specimen expected Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, November 14, 2019, 07:00 am CET -- Curetis N.V. (the " Company " and,...